About Catalym

CatalYm is targeting GDF-15, a cancer resistance mechanism, with its lead antibody, Visugromab. This therapy has shown durable anti-tumor efficacy in relapsed metastatic solid tumors when combined with anti-PD-1. CatalYm...Read More

CatalYm is targeting GDF-15, a cancer resistance mechanism, with its lead antibody, Visugromab. This therapy has shown durable anti-tumor efficacy in relapsed metastatic solid tumors when combined with anti-PD-1. CatalYm is now moving into Phase 2b trials to establish Visugromab as a new class of cancer immunotherapy across various treatments.Read Less